5 The STEP-9 trial, a 68-week, double-blind, randomized study conducted across 61 sites in 11 countries, evaluated semaglutide in people with obesity (mean BMI: 40 kg/m) and KOA with at least moderate pain
Discuss lifestyle factors : Including your current diet, exercise habits, and previous weight loss attempts
For type 2 diabetes management , NICE guidance (NG28) recommends GLP-1 agonists as second- or third-line therapy when metformin and other oral agents provide inadequate glycaemic control, or as an alternative to insulin in appropriate patients
Withrow & MacEwen's small animal clinical oncology
Jul 1 2022;23(13)doi:10.3390/ijms23137348
More details about this can be found in our CL Answer about supplement interactions with levothyroxine